Here we show that, in patients with ER positive breast cancer who have progressed on aromatase inhibitors, the addition of the FGFR inhibitor gives clinical benefit, irrespective of FGFR amplification, but especially in those whose breast cancers display a pattern of gene expression linked to FGF action. This evidence concerns the gene CYP19A1 and breast carcinoma.